Is the Severity of COVID-19 in Obese and Diabetic Patients Linked to High Serum Levels of MMP-7, MMP-9, TGF-β and PDGF Macrophage Activation Markers?
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Sohag University
- Enrollment
- 70
- Locations
- 1
- Primary Endpoint
- Measurement of matrix metalloproteinase-7 "MMP-7" serum level (pg/ml) as a biomarker of macrophage activation
Study Overview
Brief Summary
This study is aiming to find the relation between the severity of COVID-19 in diabetic and obese patients and the high serum levels of matrix metalloproteinase-7 (MMP-7),matrix metalloproteinase-9 (MMP-9), TGF-β and PDGF Macrophage Activation Markers
Detailed Description
Acute respiratory distress syndrome (ARDS) commonly occurs in COVID-19 patients who are diabetic and obese, ARDS is characterized by inflammation and pulmonary fibrosis mediated by cytokines and biomarkers released from activated alveolar macrophages, also cytokine storm may occurs leading to multiple organ failure. These sequelae of COVID-19 disease in obese and diabetic patients are attributed to elevated plasma lipopolysaccharide which is the main activator of M1 and M2 macrophages. chronic activation of macrophages leads to production of profibrotic markers as transforming growth factor-β (TGF-β), platelet-derived growth factor (PDGF), matrix metalloproteinase-7 (MMP7) and matrix metalloproteinase-9 (MMP9) which promote fibrogenesis. In this research, we measure circulatory alveolar macrophage activation markers in COVID-19 obese patients with type 1 and type 2 diabetes.
Study Design
- Study Type
- Observational
- Observational Model
- Other
- Time Perspective
- Cross Sectional
Eligibility Criteria
- Ages
- 19 Years to 70 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Overweight patients with body mass index higher than 25 and obese patients with body mass index higher than 30 were selected to be included
- •Type one and type two diabetes mellitus patients were also included
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Measurement of matrix metalloproteinase-7 "MMP-7" serum level (pg/ml) as a biomarker of macrophage activation
Time Frame: MMP-7 is measured after admission of patients to isolation hospital along 7 days interval for 21 days, 3 plasma samples are collected on the 7th day of admission, day 14 and day 21
ELISA "Enzyme linked immunosorbent assay" technique.
Measurement of matrix metalloproteinase-9 "MMP-9" serum level (pg/L) as a biomarker of macrophage activation
Time Frame: MMP-9 is measured after admission of patients to isolation hospital along 7 days interval for 21 days, 3 plasma samples are collected on the 7th day of admission, day 14 and day 21
ELISA "Enzyme linked immunosorbent assay" technique.
Measurement of transforming growth factor B "TGF-B" serum level ( pg/ml) as a biomarker of macrophage activation
Time Frame: TGF-B is measured after admission of patients to isolation hospital along 7 days interval for 21 days, 3 plasma samples are collected on the 7th day of admission, day 14 and day 21
ELISA "Enzyme linked immunosorbent assay" technique.
Measurement of platelet derived growth factor "PDGF" serum level (ng/ml) as a biomarker of macrophage activation
Time Frame: PDGF is measured after admission of patients to isolation hospital along 7 days interval for 21 days, 3 plasma samples are collected on the 7th day of admission, day 14 and day 21
ELISA "Enzyme linked immunosorbent assay" technique.
Secondary Outcomes
No secondary outcomes reported
Investigators
Nahed Fathallah Fahmy
lecturer of Medical Microbiology & Immunology department -Faculty of medicine- Sohag university
Sohag University